肺动脉高压(pulmonary arterial hypertension,PAH)是以进行性肺血管收缩和肺动脉重构,最终导致右心室衰竭为特征的疾病。与婴儿期慢性肺病(chronic lung disease,CLD)相关的PAH(PAH-CLD)被认为具有Ⅰ型(PAH)和Ⅲ型(肺疾病相关)的特征。持续性静脉输注依前列醇(epoprostenol)可用于治疗严重的PAH,但在婴儿和幼童需要通过中心静脉导管给药,易发生感染、导管破裂及血栓等并发症。此外,依前列醇的半衰期短,增加因输液中断所致的相关风险,因此,临床上需要一个新的输液系统,以减少这种 Pulmonary arterial hypertension (PAH) is a disease characterized by progressive pulmonary vasoconstriction and remodeling of the pulmonary artery, which eventually leads to right ventricular failure. PAH (PAH-CLD) associated with infantile chronic lung disease (CLD) is considered to have type I (PAH) and type III (lung disease-related) features. Persistent intravenous infusion of epoprostenol is indicated for the treatment of severe PAH, but infants and young children need to be administered through a central venous catheter. Infection, catheter rupture, and thrombus complications are more likely to occur. In addition, due to the short half-life of prostanoid, which increases the risk associated with interruption of infusion, a new infusion system is needed clinically to reduce this